Household & Personal Products · Founded 1937 · https://www.colgatepalmolive.com · BSE 500830 · NSE COLGATE PALM · ISIN INE259A01022
No Notes Added Yet
Business
Colgate-Palmolive (India) Ltd. is a leading Fast-Moving Consumer Goods (FMCG) company primarily engaged in the manufacturing and marketing of oral care products, alongside a smaller portfolio of personal care and home care products. Its core business model involves developing, producing, distributing, and extensively marketing these consumer goods across India. The company makes money by selling its products through a vast retail network, including general trade, modern trade, e-commerce, and pharmacies, catering to a wide consumer base. Oral care, particularly toothpaste, is its dominant segment.
Revenue Mix
Colgate-Palmolive (India) Ltd.'s revenue is predominantly driven by its oral care segment, which includes toothpastes, toothbrushes, and mouthwashes. This segment accounts for the vast majority of its total revenue, demonstrating the company's strong focus and market leadership in oral hygiene. The company also has a presence in personal care products (e.g., soaps, shower gels) and home care products, but these contribute a significantly smaller portion to its overall revenue.
Industry
The Indian FMCG industry is large, diverse, and highly competitive, characterized by extensive distribution requirements, strong brand loyalty, and price sensitivity. Colgate-Palmolive (India) Ltd. holds a formidable position as the market leader in the oral care segment, particularly in toothpaste, for several decades. It competes with other multinational FMCG giants (e.g., Hindustan Unilever, Procter & Gamble) as well as strong domestic players (e.g., Dabur, Patanjali, Marico) across its product categories. Its brand "Colgate" has near-ubiquitous recognition, especially in oral care.
MOAT
Brand Equity & Trust: "Colgate" is one of the most recognized and trusted brands in India, almost synonymous with toothpaste. This strong brand loyalty built over decades creates a significant barrier to entry.
Extensive Distribution Network: The company possesses a deep and wide distribution reach across urban, semi-urban, and rural India, ensuring product availability even in remote areas.
Scale of Operations: As a large-scale player, it benefits from economies of scale in manufacturing, procurement, and marketing, leading to cost efficiencies.
Product Dominance: Its overwhelming market share in the core toothpaste category gives it pricing power and shelf space advantage.
Parent Company Support: Leverage global R&D, product innovation, and best practices from its parent, Colgate-Palmolive Company.
Growth Drivers
Premiumization: Driving consumers towards higher-value, specialized, and therapeutic oral care products (e.g., whitening, sensitive, ayurvedic, mouthwashes).
Rural Penetration: Expanding reach and increasing consumption in underserved rural and semi-urban markets, where per capita consumption can still grow.
Innovation & New Product Development: Introducing new variants, formats, and extending into adjacent categories to capture evolving consumer needs and preferences.
Increased Per Capita Consumption: Low per capita consumption of oral care products in India compared to developed markets offers a significant long-term growth runway.
Health & Hygiene Awareness: Growing awareness about oral hygiene benefits can drive category expansion.
Risks
Intense Competition: Aggressive competition from both established players and new entrants, including fast-growing Ayurvedic/natural brands and direct-to-consumer models, can pressure market share and margins.
Raw Material Price Volatility: Fluctuations in the prices of key raw materials, packaging materials, and energy can impact profitability.
Changing Consumer Preferences: A significant shift in consumer preferences towards natural/herbal products or value-for-money alternatives could challenge its conventional product portfolio.
Regulatory Changes: Potential changes in advertising norms, product ingredient regulations, or environmental policies could impact operations.
Economic Slowdown: A general economic slowdown affecting consumer spending power could temper growth in premium segments.
Management & Ownership
Colgate-Palmolive (India) Ltd. is a subsidiary of the global Colgate-Palmolive Company (USA). The management team is professional and experienced, combining global expertise with deep understanding of the Indian market. The ownership structure is primarily held by its US parent company, with a significant portion of shares publicly traded on Indian stock exchanges. This arrangement typically ensures strong corporate governance and access to global resources, technology, and R&D.
Outlook
Colgate-Palmolive (India) Ltd. is poised to benefit from its strong brand equity, extensive distribution, and the long-term growth potential of the Indian FMCG market, particularly in oral care. The company's leadership position in a category with relatively low per capita consumption provides a foundation for continued growth through premiumization and deeper market penetration. However, the outlook is not without challenges. Intense competition, particularly from players focusing on the "natural" segment, and potential shifts in consumer preferences demand continuous innovation and aggressive marketing efforts. While the core oral care segment is mature, opportunities in specialized products and expanding its personal care footprint could offer diversification. The company's ability to navigate competitive pressures, manage input costs effectively, and maintain its innovation pipeline will be crucial for sustaining its market dominance and driving consistent, albeit potentially moderate, growth in revenue and profitability.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1396 | 1490 | 1497 | 1619 | 1462 | 1463 | 1434 | 1520 | 1486 | 1595 |
| Other Income | 18 | 23 | 23 | 76 | 20 | 19 | 18 | 15 | 39 | 17 |
| Total Income | 1414 | 1513 | 1520 | 1695 | 1482 | 1482 | 1452 | 1535 | 1525 | 1612 |
| Total Expenditure | 927 | 958 | 988 | 1122 | 1007 | 965 | 981 | 1054 | 1044 | 1086 |
| Operating Profit | 486 | 555 | 532 | 573 | 475 | 517 | 471 | 480 | 481 | 527 |
| Interest | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 41 | 42 | 42 | 42 | 41 | 38 | 38 | 37 | 36 | 35 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8 | -17 |
| Profit Before Tax | 443 | 511 | 489 | 530 | 433 | 478 | 432 | 442 | 436 | 474 |
| Provision for Tax | 113 | 132 | 125 | 135 | 110 | 123 | 111 | 115 | 112 | 121 |
| Profit After Tax | 330 | 380 | 364 | 395 | 323 | 355 | 321 | 328 | 324 | 353 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 330 | 380 | 364 | 395 | 323 | 355 | 321 | 328 | 324 | 353 |
| Adjusted Earnings Per Share | 12.1 | 14 | 13.4 | 14.5 | 11.9 | 13.1 | 11.8 | 12 | 11.9 | 13 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3982 | 3868 | 3982 | 4188 | 4462 | 4525 | 4841 | 5100 | 5226 | 5680 | 6040 | 6035 |
| Other Income | 33 | 40 | 41 | 37 | 38 | 49 | 30 | 26 | 54 | 77 | 139 | 89 |
| Total Income | 4015 | 3908 | 4023 | 4225 | 4500 | 4574 | 4872 | 5126 | 5280 | 5757 | 6179 | 6124 |
| Total Expenditure | 3160 | 2930 | 3038 | 3074 | 3226 | 3323 | 3332 | 3534 | 3679 | 3780 | 4082 | 4165 |
| Operating Profit | 855 | 978 | 985 | 1151 | 1274 | 1251 | 1540 | 1592 | 1601 | 1977 | 2097 | 1959 |
| Interest | 0 | 0 | 0 | 0 | 2 | 10 | 7 | 6 | 5 | 5 | 4 | 4 |
| Depreciation | 75 | 111 | 133 | 157 | 159 | 198 | 182 | 177 | 175 | 172 | 163 | 146 |
| Exceptional Income / Expenses | 0 | -31 | 0 | -12 | 31 | 0 | 0 | 0 | -11 | -20 | 0 | -25 |
| Profit Before Tax | 780 | 835 | 851 | 983 | 1143 | 1043 | 1350 | 1409 | 1410 | 1781 | 1930 | 1784 |
| Provision for Tax | 221 | 254 | 274 | 310 | 367 | 227 | 315 | 331 | 363 | 458 | 493 | 459 |
| Profit After Tax | 559 | 581 | 577 | 673 | 776 | 816 | 1035 | 1078 | 1047 | 1324 | 1437 | 1326 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 559 | 581 | 577 | 673 | 776 | 816 | 1035 | 1078 | 1047 | 1324 | 1437 | 1326 |
| Adjusted Earnings Per Share | 20.6 | 21.4 | 21.2 | 24.8 | 28.5 | 30 | 38.1 | 39.6 | 38.5 | 48.7 | 52.8 | 48.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 6% | 6% | 6% | 4% |
| Operating Profit CAGR | 6% | 10% | 11% | 9% |
| PAT CAGR | 9% | 10% | 12% | 10% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -14% | 9% | 4% | 9% |
| ROE Average | 81% | 72% | 73% | 65% |
| ROCE Average | 109% | 97% | 97% | 89% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 770 | 1031 | 1274 | 1525 | 1447 | 1594 | 1166 | 1735 | 1716 | 1874 | 1664 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 78 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 65 | 427 | 717 | 1408 | 1538 | 140 | 2164 | 1738 | 2096 | 2060 | 2951 |
| Total Current Liabilities | 1973 | 1847 | 1900 | 1557 | 1839 | 1658 | 2405 | 2598 | 2600 | 3223 | 2396 |
| Total Liabilities | 2808 | 3305 | 3891 | 4490 | 4901 | 3391 | 5736 | 6070 | 6412 | 7158 | 7012 |
| Fixed Assets | 782 | 1008 | 1108 | 1146 | 1191 | 1123 | 1065 | 963 | 862 | 794 | 776 |
| Other Non-Current Assets | 231 | 618 | 1010 | 1709 | 1912 | 469 | 2511 | 2109 | 2487 | 2476 | 3354 |
| Total Current Assets | 1796 | 1679 | 1773 | 1635 | 1798 | 1800 | 2160 | 2998 | 3063 | 3888 | 2881 |
| Total Assets | 2808 | 3305 | 3891 | 4490 | 4901 | 3391 | 5736 | 6070 | 6412 | 7158 | 7012 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 151 | 133 | 193 | 199 | 305 | 378 | 398 | 297 | 724 | 806 | 889 |
| Cash Flow from Operating Activities | 638 | 689 | 688 | 694 | 983 | 930 | 784 | 1626 | 1176 | 1199 | 1394 |
| Cash Flow from Investing Activities | -272 | -237 | -342 | -207 | -96 | -19 | 71 | -108 | -8 | 79 | 56 |
| Cash Flow from Financing Activities | -385 | -391 | -341 | -380 | -815 | -891 | -956 | -1091 | -1087 | -1195 | -1671 |
| Net Cash Inflow / Outflow | -18 | 61 | 5 | 107 | 73 | 20 | -101 | 427 | 82 | 83 | -221 |
| Closing Cash & Cash Equivalent | 132 | 193 | 199 | 305 | 378 | 398 | 297 | 724 | 806 | 889 | 668 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 20.55 | 21.37 | 21.23 | 24.76 | 28.52 | 30.02 | 38.07 | 39.65 | 38.5 | 48.66 | 52.82 |
| CEPS(Rs) | 23.31 | 25.46 | 26.13 | 30.51 | 34.37 | 37.3 | 44.78 | 46.16 | 44.93 | 54.97 | 58.81 |
| DPS(Rs) | 24 | 10 | 10 | 24 | 23 | 28 | 38 | 40 | 39 | 58 | 51 |
| Book NAV/Share(Rs) | 28.32 | 37.49 | 46.63 | 55.84 | 53.05 | 58.64 | 42.88 | 63.7 | 63.27 | 68.98 | 61.71 |
| Core EBITDA Margin(%) | 19.4 | 21.58 | 20.87 | 25.73 | 27.63 | 26.38 | 31.01 | 30.55 | 29.44 | 33.29 | 32.22 |
| EBIT Margin(%) | 18.41 | 19.21 | 18.84 | 22.71 | 25.59 | 23.11 | 27.88 | 27.6 | 26.92 | 31.28 | 31.82 |
| Pre Tax Margin(%) | 18.41 | 19.21 | 18.84 | 22.71 | 25.54 | 22.9 | 27.73 | 27.49 | 26.82 | 31.2 | 31.75 |
| PAT Margin (%) | 13.19 | 13.36 | 12.77 | 15.56 | 17.34 | 17.92 | 21.27 | 21.03 | 19.93 | 23.18 | 23.64 |
| Cash Profit Margin (%) | 14.96 | 15.92 | 15.72 | 19.17 | 20.89 | 22.27 | 25.02 | 24.49 | 23.25 | 26.19 | 26.32 |
| ROA(%) | 21.55 | 19.01 | 16.05 | 16.07 | 16.52 | 19.69 | 22.69 | 18.27 | 16.78 | 19.51 | 20.28 |
| ROE(%) | 81.59 | 64.94 | 50.48 | 48.32 | 52.37 | 53.75 | 75 | 74.4 | 60.65 | 73.59 | 80.84 |
| ROCE(%) | 113.91 | 92.74 | 73.88 | 70.26 | 74.97 | 67.41 | 98.37 | 97.56 | 81.98 | 99.5 | 109.31 |
| Receivable days | 5.36 | 7.18 | 9.34 | 13.95 | 16.76 | 13.71 | 9.36 | 12.17 | 13.27 | 10.38 | 11.82 |
| Inventory Days | 20.58 | 22.82 | 23.58 | 21.89 | 19.39 | 21.85 | 23.72 | 24.67 | 24.05 | 20.2 | 20.23 |
| Payable days | 125.89 | 131.83 | 142.09 | 149.28 | 144.43 | 142.22 | 161.72 | 167.65 | 155.88 | 174.03 | 180.94 |
| PER(x) | 48.98 | 38.73 | 47.02 | 42.72 | 44.13 | 41.74 | 40.97 | 38.88 | 39.14 | 55.71 | 45.27 |
| Price/Book(x) | 35.55 | 22.08 | 21.41 | 18.94 | 23.72 | 21.37 | 36.37 | 24.2 | 23.82 | 39.3 | 38.75 |
| Dividend Yield(%) | 1.19 | 1.21 | 1 | 2.27 | 1.83 | 2.23 | 2.44 | 2.59 | 2.59 | 2.14 | 2.13 |
| EV/Net Sales(x) | 6.81 | 5.74 | 6.75 | 6.76 | 7.6 | 7.44 | 8.58 | 8.07 | 7.67 | 12.74 | 10.59 |
| EV/Core EBITDA(x) | 31.71 | 22.72 | 27.28 | 24.59 | 26.62 | 26.91 | 26.98 | 25.86 | 25.03 | 36.6 | 30.49 |
| Net Sales Growth(%) | 11.26 | -2.86 | 2.94 | 5.18 | 6.55 | 1.4 | 6.99 | 5.34 | 2.48 | 8.69 | 6.33 |
| EBIT Growth(%) | 7.2 | 7.03 | 1.93 | 15.46 | 16.48 | -8.04 | 28.92 | 4.23 | -0.02 | 26.28 | 8.28 |
| PAT Growth(%) | 3.54 | 3.97 | -0.64 | 16.62 | 15.18 | 5.27 | 26.81 | 4.15 | -2.89 | 26.41 | 8.55 |
| EPS Growth(%) | 3.54 | 3.97 | -0.64 | 16.62 | 15.18 | 5.27 | 26.81 | 4.15 | -2.89 | 26.4 | 8.55 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0.06 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 0.91 | 0.91 | 0.93 | 1.05 | 0.98 | 1.09 | 0.9 | 1.15 | 1.18 | 1.21 | 1.2 |
| Quick Ratio(x) | 0.78 | 0.75 | 0.78 | 0.9 | 0.84 | 0.91 | 0.76 | 1.02 | 1.05 | 1.11 | 1.05 |
| Interest Cover(x) | 0 | 0 | 0 | 0 | 458.88 | 109.51 | 187.01 | 240.02 | 287.88 | 357.27 | 447.72 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 51 | 51 | 51 | 51 | 51 | 51 | 51 | 51 | 51 | 51 |
| FII | 24.62 | 24.51 | 24.44 | 24.94 | 23.72 | 22.22 | 20.39 | 17.16 | 15.18 | 13.6 |
| DII | 5.88 | 6.1 | 6.01 | 5.84 | 6.84 | 8.12 | 9.62 | 12.24 | 13.79 | 15.53 |
| Public | 18.5 | 18.39 | 18.55 | 18.23 | 18.44 | 18.65 | 18.99 | 19.6 | 20.03 | 19.87 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 |
| FII | 6.7 | 6.67 | 6.65 | 6.78 | 6.45 | 6.04 | 5.54 | 4.67 | 4.13 | 3.7 |
| DII | 1.6 | 1.66 | 1.63 | 1.59 | 1.86 | 2.21 | 2.62 | 3.33 | 3.75 | 4.22 |
| Public | 5.03 | 5 | 5.04 | 4.96 | 5.02 | 5.07 | 5.17 | 5.33 | 5.45 | 5.4 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +6% | +6% | +6% | +4% |
| Operating Profit CAGR | +6% | +10% | +11% | +9% |
| PAT CAGR | +9% | +10% | +12% | +10% |
| Share Price CAGR | -14% | +9% | +4% | +9% |
| ROE Average | +81% | +72% | +73% | +65% |
| ROCE Average | +109% | +97% | +97% | +89% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 51 | 51 | 51 | 51 | 51 | 51 | 51 | 51 | 51 | 51 |
| FII | 24.62 | 24.51 | 24.44 | 24.94 | 23.72 | 22.22 | 20.39 | 17.16 | 15.18 | 13.6 |
| DII | 5.88 | 6.1 | 6.01 | 5.84 | 6.84 | 8.12 | 9.62 | 12.24 | 13.79 | 15.53 |
| Public | 49 | 49 | 49 | 49 | 49 | 49 | 49 | 49 | 49 | 49 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 | 13.87 |
| FII | 6.7 | 6.67 | 6.65 | 6.78 | 6.45 | 6.04 | 5.54 | 4.67 | 4.13 | 3.7 |
| DII | 1.6 | 1.66 | 1.63 | 1.59 | 1.86 | 2.21 | 2.62 | 3.33 | 3.75 | 4.22 |
| Public | 13.33 | 13.33 | 13.33 | 13.33 | 13.33 | 13.33 | 13.33 | 13.33 | 13.33 | 13.33 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 | 27.2 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.